Compare LSCC & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSCC | ASND |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 15.2B |
| IPO Year | 1994 | 2014 |
| Metric | LSCC | ASND |
|---|---|---|
| Price | $129.19 | $253.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $103.75 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 1.8M | 626.3K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $385,961,000.00 | N/A |
| Revenue This Year | $36.12 | $96.35 |
| Revenue Next Year | $19.98 | $44.91 |
| P/E Ratio | $863.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $46.48 | $161.09 |
| 52 Week High | $157.01 | $282.15 |
| Indicator | LSCC | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 49.74 |
| Support Level | $128.23 | $213.28 |
| Resistance Level | $155.94 | $282.15 |
| Average True Range (ATR) | 6.55 | 7.76 |
| MACD | -0.14 | -3.04 |
| Stochastic Oscillator | 47.72 | 12.90 |
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.